• In late April 2026, Bausch + Lomb raised its 2026 revenue guidance to US$5.42–US$5.52 billion and showcased more than 40 scientific data presentations across its eye health portfolio and pipeline at the ARVO 2026 meeting, while also advancing B‑vitamin–based AMD research and launching PreserVision AREDS3 in the U.S.
• Together, the upgraded outlook and breadth of clinical and pipeline data underscored how Bausch + Lomb is tying science-led innovation directly to its commercial growth ambitions in pharmaceuticals, vision care and surgical products.
• We’ll now examine how the higher 2026 revenue guidance, alongside expanded clinical evidence across key franchises, affects Bausch + Lomb’s investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Bausch + Lomb Investment Narrative Recap

To own Bausch + Lomb, you need to believe that its broad eye health portfolio can convert scientific depth into consistent commercial execution across pharma, vision care and surgical products. The raised 2026 revenue guidance to US$5.42–US$5.52 billion modestly reinforces that case, while also putting more attention on near term delivery under the Vision 27 margin program. The biggest risk remains execution across many moving parts rather than any single ARVO data set.

The announcement that Bausch + Lomb will present more than 40 data sets at ARVO 2026, covering products from Miebo and Xiidra to enVista Envy and pipeline glaucoma and AMD assets, is especially relevant here. It helps link the higher 2026 revenue guidance to a visible stream of clinical evidence across prescription therapies, premium lenses and consumer brands, which are central to both the company’s short term growth drivers and its longer term differentiation story.

Yet, against this backdrop of upgraded guidance and rich clinical data, the operational complexity of Vision 27 still exposes investors to risks that they should be aware of...

Bausch + Lomb's narrative projects $5.9 billion revenue and $252.2 million earnings by 2028. This requires 5.7% yearly revenue growth and a $557.2 million earnings increase from $-305.0 million today.

Uncover how Bausch + Lomb's forecasts yield a $17.25 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$6.0 billion and earnings US$242.7 million by 2028, so if you are comparing that bullish view with concerns about Vision 27 execution risk, this new guidance and ARVO data could eventually shift how both the upside and the operational risks are weighed.

Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth just $17.25!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.